Elevance Health, Inc. (ELV) Financials
PeriodQ3 FY2026
Published
Elevance Health reported $51.43 billion in revenue for Q3 FY2026, the quarter ended September 30, 2026, up 1.4% from a year earlier, and net income attributable to shareholders of $1.36 billion, up 14.8%, or $6.27 per diluted share, up 17.9%. Higher net investment income, $1.04 billion against $625 million a year earlier, drove the increase, while total operating gain across its segments was $1.27 billion, down 2.0%. The benefit expense ratio, benefit expense as a percentage of premiums, was 90.6%, down 0.7 points from a year earlier.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $51,429,000,000 | up 1.4% |
| Net income | $1,365,000,000 | up 14.8% |
| Diluted EPS | $6.27 | up 17.9% |
| Benefit expense ratio | 90.6% | down 0.7 points |
| Net investment income | $1,037,000,000 | up 65.9% |
| Operating gain | $1,269,000,000 | down 2.0% |
Company details
| Name | Elevance Health, Inc. |
|---|---|
| Ticker | ELV |
| CIK | 0001156039 |
| Exchange | NYSE |
| State | Indiana |
| Incorporation | Indiana |
| SIC | 6324 |
| Office | Finance |
| Industry | Hospital & Medical Service Plans |
| Latest period covered | Q3 FY2026, ended 2026-09-30, 10-Q, accession 0001156039-26-000071 |
| Fiscal year end | 12/31 (MM/DD) |
| Next expected filing | 10-K around 2027-02-05 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included, plus a figure_sources block linking each figure the filing tags to the line that prints it.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Elevance Health Q3 FY2026
What was Elevance Health's revenue in Q3 FY2026?
Elevance Health reported total revenues of $51.43 billion for Q3 FY2026, the quarter ended September 30, 2026. That is up 1.4% from $50.71 billion in the same quarter a year earlier.
How much did Elevance Health earn in Q3 FY2026?
Elevance Health's net income attributable to shareholders was $1.36 billion in Q3 FY2026, up 14.8% from $1.19 billion a year earlier. Diluted earnings per share were $6.27, against $5.32 in the same quarter a year earlier.
What was Elevance Health's benefit expense ratio in Q3 FY2026?
Elevance Health's benefit expense ratio, benefit expense as a percentage of premiums, was 90.6% in Q3 FY2026, down 0.7 points from 91.3% a year earlier.
Why did Elevance Health's earnings rise in Q3 FY2026?
Elevance Health's earnings rose in Q3 FY2026 mainly on higher net investment income, which was $1.04 billion against $625 million a year earlier. Total operating gain across its segments, measured before investment results, interest expense, amortization of intangible assets and income taxes, was $1.27 billion, down 2.0% from $1.29 billion.
Where can I get Elevance Health, Inc. (ELV) financial data in machine-readable form?
Ticker Scout publishes Elevance Health, Inc.'s financial statements as JSON at https://tickerscout.ai/elv/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/elv/narrative.md and https://tickerscout.ai/elv/events.md. Elevance Health, Inc.'s SEC CIK is 0001156039. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Elevance Health, Inc. (ELV) next file with the SEC?
Elevance Health, Inc. (ELV) is expected to file its next Form 10-K with the SEC on or around February 5, 2027. That date is a projection rather than a company-announced date: it is derived from Elevance Health, Inc.'s own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q3 FY2026, the period ended 2026-09-30, SEC accession 0001156039-26-000071.
Related companies
How this page was built
This page was built from Elevance Health, Inc.'s own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names three such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.